10-Q: Glaukos Corp. Q2 2026 Sales Surge 50%, Driven by iDose TR

Glaukos Corporation reported a significant 50% increase in net sales for the second quarter of 2026, reaching $185.6 million, primarily fueled by strong performance of its iDose TR product.

Summary

• Glaukos Corporation reported a 50% year-over-year increase in net sales for the second quarter of 2026, reaching $185.6 million, and a 46% increase for the first six months to $336.2 million.
• The growth was primarily driven by strong sales of the iDose TR product in the U.S. glaucoma market, which saw a 64% increase in net sales for the quarter.
• Corneal health product sales also increased by 48% for the quarter, largely due to the launch of Epioxa.
• The company reported a net loss of $18.4 million for the quarter, a slight improvement from the $19.7 million loss in the same period last year.
• Operating expenses increased by 41% to $168.9 million for the quarter, driven by higher selling, general, and administrative (SG&A) expenses and research and development (R&D) costs.
• The company ended the quarter with $286.2 million in cash, cash equivalents, and short-term investments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth and improved gross margins, although the continued net loss and increased operating expenses warrant monitoring.

Positives

• Net sales increased by 50% to $185.6 million for the three months ended June 30, 2026, compared to $124.1 million for the same period in 2025.
• U.S. glaucoma product net sales increased by 64% to $118.5 million for the three months ended June 30, 2026.
• iDose TR sales volume and higher net sales price significantly contributed to the revenue growth.
• Corneal health product net sales increased by 48% to $30.4 million for the three months ended June 30, 2026.
• Gross margin improved to 82% for the three months ended June 30, 2026, from 78% in the prior year period.
• Net loss decreased by 7% to $18.4 million for the three months ended June 30, 2026, from $19.7 million in the prior year period.
• Cash, cash equivalents, and short-term investments totaled $286.2 million as of June 30, 2026.

Negatives

• The company incurred a net loss of $18.4 million for the three months ended June 30, 2026.
• Total operating expenses increased by 41% to $168.9 million for the three months ended June 30, 2026.
• Selling, general, and administrative (SG&A) expenses increased by 39% to $116.1 million for the three months ended June 30, 2026.
• Research and development (R&D) expenses increased by 40% to $51.3 million for the three months ended June 30, 2026.
• The company has an accumulated deficit of $971.3 million as of June 30, 2026.
• International glaucoma sales growth was partially offset by reimbursement challenges in Germany.
• The company is transitioning commercial efforts and manufacturing from Photrexa to Epioxa, which may cause market access pathway establishment challenges.

Risks

• Failure to achieve commercial success of iDose TR or Epioxa products could materially impact the business.
• Unfavorable global and regional economic conditions, including inflation and supply shortages, could harm business operations.
• Supply and/or manufacturing disruptions impacting key products could reduce gross margins and negatively impact operating results.
• The company may not reach sustained profitability.
• Compliance with applicable healthcare regulations is costly, and failure to comply could harm financial condition and operating results.
• Intellectual property claims or litigation could be costly and interfere with product commercialization.
• The company faces risks associated with its international operations, including varying regulatory processes and intellectual property protection.
• The company is subject to legal proceedings, including a complaint against SpyGlass Pharma, Inc. and its Vice President of Clinical Research.

Future Outlook

The company anticipates potential disruption in its U.S. Corneal Health franchise during 2026 as it transitions from Photrexa to Epioxa. Reimbursement pathways for Epioxa are still being established. The company expects capital expenditures to be higher in 2026 than in 2025 due to upgrades in manufacturing facilities and technologies, and continued investment in R&D equipment. Construction for a new R&D and manufacturing facility in Huntsville, Alabama, is anticipated to begin in 2026, with over $80.0 million in capital expenditures expected over the project's multi-year duration.

Management Comments

• "Now that reimbursement for the iDose TR drug and procedure for Medicare fee for service patients has become more timely and consistent across all MACs, we have begun seeing increased utilization of iDose TR by our customers..."
• "We estimate that approximately 80% of procedures utilizing our iDose TR and iStent family of products in the U.S. have been performed in the ASC setting and the remaining estimated 20% of procedures have been performed in the hospital."
• "As an in-office procedure, the procedural component of Epioxa will be covered by a temporary Category III CPT code, 0402T, which is the same code used currently for Photrexa."
• "We believe that cash from operating, financing and investing activities, together with our cash and investment balances, will be sufficient to meet ongoing operations, capital expenditures, commitments, working capital requirements and other known contractual and other obligations and satisfy our liquidity requirements for at least the next 12 months and the foreseeable future."

Industry Context

StockSavvy.ai notes that Glaukos' strong sales growth in Q2 2026, particularly with its iDose TR product, aligns with the broader trend in the ophthalmic market towards innovative, sustained-release therapies and less invasive procedures. The company's strategic focus on glaucoma, corneal disorders, and retinal diseases positions it well within a growing segment of the healthcare industry, though competition and evolving reimbursement landscapes remain key factors.

Comparison to Industry Standards

• Glaukos' Q2 2026 net sales growth of 50% significantly outpaces the typical growth rates seen in the broader medical device and pharmaceutical sectors, which often range from single digits to low double digits annually.
• The company's gross margin of 82% is strong and generally above the industry average for medical device companies, reflecting efficient manufacturing and pricing power for its specialized products.
• The continued net loss, while improving, is not uncommon for companies in the growth phase of product commercialization, especially those investing heavily in R&D and sales infrastructure, such as Johnson & Johnson's MedTech segment or Alcon.
• The significant increase in R&D spending (40% year-over-year) reflects a commitment to innovation, a common strategy among leading ophthalmic companies like Zeiss Meditec and Bausch Health, to maintain a competitive edge.

Legal Proceedings

• Glaukos filed a complaint against SpyGlass Pharma, Inc. and Long Doan alleging theft and exploitation of confidential files. An injunction was entered against both defendants. The court denied motions to dismiss all claims. SpyGlass filed counterclaims, to which Glaukos moved to dismiss. Doan also filed counterclaims. A trial date is set for January 26, 2027.

Stakeholder Impact

• Shareholders: Potential for increased share value due to strong sales growth, but offset by continued net losses and increased operating expenses. The company's stock price may be influenced by the success of iDose TR and Epioxa commercialization and reimbursement developments.
• Employees: Increased stock-based compensation expense noted, reflecting investment in personnel and performance-based awards. Continued growth may lead to further hiring and career opportunities.
• Customers (Healthcare Providers): Continued innovation in glaucoma and corneal treatments offers advanced options. Transition from Photrexa to Epioxa may require adaptation.
• Suppliers: Potential for increased demand for raw materials and components due to higher production volumes.

Next Steps

• Transition commercial efforts and manufacturing from Photrexa to Epioxa, projected to conclude by the end of Q3 2026.
• Continue to monitor developments regarding proposed Local Coverage Determinations (LCDs) for iDose TR.
• Establish market access pathways for Epioxa.
• Upgrade certain manufacturing facilities and technologies.
• Invest in R&D equipment to advance the product pipeline.
• Begin construction of a new R&D and manufacturing facility in Huntsville, Alabama.

Key Dates

Recommendation

The company demonstrates strong top-line growth driven by key products like iDose TR and Epioxa, with improving gross margins. However, continued operating losses, significant R&D and SG&A investments, and ongoing reimbursement uncertainties for iDose TR necessitate a cautious approach. While the growth trajectory is positive, the path to sustained profitability requires further validation and successful navigation of regulatory and market access challenges. Therefore, a 'hold' recommendation is appropriate pending clearer visibility on profitability and resolution of reimbursement concerns.

Keywords

Glaucoma Treatment, Ophthalmic Therapies, iDose TR, Epioxa, Corneal Disorders, Medical Technology, Pharmaceuticals, Micro-Invasive Glaucoma Surgery